PHILADELPHIA, PA., May 24, 2016 -- The Center for Information and Study on Clinical Research Participation (CISCRP), an independent non-profit organization, is excited to announce its upcoming Medical Heroes Appreciation 5K Fun Run & Walk in Philadelphia, PA to honor the volunteers who give the gift of participation in clinical research and to raise awareness about the importance of clinical research in advancing public health.
The event will take place on Monday, June 27, 2016 from 6:30-8:15am, in conjunction with the DIA 2016 meeting. The start/finish location is at 1 Boathouse Row. Participants are encouraged to register early as space is limited. To register, visit ciscrp.org/medhero5k-philadelphia. On behalf of every 5K registrant, the Greater Gift Initiative will also donate one vaccine to a child in need.
"Through their participation in clinical trials each year, millions of people are Medical Heroes, helping to advance public health and knowledge about disease and new treatments," said CISCRP's Founder and Board Chair Ken Getz. "With this special event, we continue to recognize their gift of participation, raise public awareness, and express our gratitude and admiration."
Event sponsors and supporters see the 5K as a unique opportunity to celebrate clinical study volunteers for their participation. "We're proud to partner with CISCRP on many of its public and patient serving initiatives including the Medical Heroes Appreciation 5K, which gives us the opportunity to put our best foot forward in recognizing and expressing gratitude for clinical trial volunteers," said Paulo Moreira, VP - GCO, Head of External Innovation at EMD Serono, which has served as a Champion supporter for each Medical Heroes Appreciation 5K since the initiative's 2014 inception.
Early check-in will be hosted throughout the day at the DIA 2016 registration area in the Pennsylvania Convention Center on Sunday, June 26. Check-in on the day of the event begins at 6am, and the 5K will begin at 6:30am. For more information about the event, to volunteer, register or become a sponsor, visit ciscrp.org/medhero5k-philadelphia or call toll free 1-877-MED-HERO (1-877-633-4376). Questions about sponsorship opportunities can go directly to [email protected].
About CISCRP
CISCRP is a 501(c)(3) non-profit organization dedicated to engaging the public and patients as partners in the clinical research process. CISCRP provides free education and outreach to the general public and patient communities. Visit www.CISCRP.org for more information or to support CISCRP.
|
|||||
A photo accompanying this release is available at:
http://www.globenewswire.com/newsroom/prs/?pkgid=40340
CONTACT: Danielle Lavieri
Marketing and Communications Manager
617-725-2750
[email protected]


Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Italy Fines Apple €98.6 Million Over App Store Dominance
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



